Renal Cell Carcinoma

Development of Primary Resistant Disease in mRCC Linked to Worse Survival Outcomes
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Advertisement

Latest News

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News